Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure
| Autor: | Jun-ichi Kadota, Munenori Kotoku, Shigeru Naono, Yoshiyuki Kawano, Akira Tamura |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male Central sleep apnea Heart disease Polysomnography Adrenergic beta-Antagonists Carbazoles Critical Care and Intensive Care Medicine Statistics Nonparametric Propanolamines medicine Humans Carvedilol Aged Heart Failure Ejection fraction Chi-Square Distribution medicine.diagnostic_test business.industry Sleep apnea Middle Aged medicine.disease Sleep Apnea Central Apnea–hypopnea index Echocardiography Heart failure Anesthesia Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Chest. 131(1) |
| ISSN: | 0012-3692 |
| Popis: | We sought to examine the relationship between use of beta-blockers and the severity of central sleep apnea (CSA) in patients with chronic heart failure.We performed polysomnography in 45 patients with chronic heart failure (New York Heart Association functional class II/III and left ventricular ejection fraction50%) and examined the relationship between use of beta-blockers and the severity of CSA. Central apnea index (CAI) was used as an indicator of CSA.Patients receiving beta-blockers (ie, carvedilol; n = 27) had lower apnea-hypopnea index (AHI) and CAI than patients not receiving beta-blockers (n = 18) [mean +/- SD, 14 +/- 11 vs 33 +/- 17, p0.0001; and 1.9 +/- 3.2 vs 11 +/- 12, p = 0.0004, respectively]. AHI and CAI were negatively correlated with the dose of carvedilol (Spearman rho = - 0.61, p0.0001; and Spearman rho = - 0.57, p = 0.0002, respectively). Multiple regression analysis selected no use of beta-blockers as an independent factor of CAI (p = 0.0006). In five patients with CAI5 who underwent serial sleep studies, CAI decreased significantly after 6 months of treatment with carvedilol (9.5 +/- 4.9 to 1.3 +/- 2.4, p = 0.03).In patients with chronic heart failure, CAI was lower according to the dose of beta-blockers, and no use of beta-blockers was independently associated with CAI. In addition, 6 months of treatment with carvedilol decreased CAI. These results suggest that beta-blocker therapy may dose-dependently suppress CSA in patients with chronic heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|